Catalyst Pharmaceuticals Inc represents a commitment to excellence and innovation in the pharmaceutical industry. With a focus on developing and commercializing impactful medications, Catalyst aims to improve the quality of life for patients worldwide. The company's corporate philosophy centers around integrity, transparency, and a patient-centric approach. By employing cutting-edge research and collaboration with healthcare professionals, Catalyst strives to deliver groundbreaking therapies that address significant unmet medical needs. With a strong emphasis on scientific rigor and ethical practices, Catalyst Pharmaceuticals Inc demonstrates a dedication to providing effective and safe treatments to individuals suffering from various medical conditions.

Catalyst Pharmaceuticals Inc is primarily present in the United States.

Catalyst Pharmaceuticals Inc has achieved several significant milestones. The company received FDA approval for its drug Firdapse, which is used to treat Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. This approval was a major achievement for Catalyst Pharmaceuticals Inc as it marked the first FDA-approved treatment for LEMS. The company also successfully completed a Phase 3 clinical trial for Firdapse, demonstrating its efficacy and safety. Furthermore, Catalyst Pharmaceuticals Inc has obtained Orphan Drug Designation from the FDA for Firdapse, providing the company with market exclusivity for the treatment of LEMS. These milestones showcase the company's dedication to developing innovative treatments and positioning itself as a leader in rare diseases.

Catalyst Pharmaceuticals Inc, founded in 2002, is a biopharmaceutical company specializing in the development of innovative therapies for rare neurological disorders. Headquartered in Coral Gables, Florida, Catalyst is dedicated to addressing unmet medical needs and improving the quality of life for patients. With a focus on orphan drug development and personalized medicine, Catalyst has been at the forefront of research and development in the rare disease space. The company is driven by a passionate team of professionals committed to making a meaningful impact in the lives of patients and their families. Catalyst Pharmaceuticals Inc has established itself as a leading player in the pharmaceutical industry, continuously striving towards breakthrough treatments.

The main competitors of Catalyst Pharmaceuticals Inc in the market are other pharmaceutical companies that specialize in the same therapeutic areas as Catalyst. These competitors include companies such as BioMarin Pharmaceutical Inc, Retrophin Inc, and Amicus Therapeutics Inc. These companies operate within the same industry and are engaged in the development and commercialization of treatments for rare diseases, similar to Catalyst Pharmaceuticals Inc. Enduring competition in the pharmaceutical market necessitates Catalyst to continuously innovate and differentiate itself to maintain a competitive edge and capture a larger market share.

Catalyst Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Catalyst Pharmaceuticals Inc is focused on the development and commercialization of innovative therapies for rare neurological disorders. Catalyst's mission is to improve the lives of patients by providing effective treatments. They leverage their expertise in drug development, clinical research, and regulatory affairs to identify, develop, and bring promising therapies to market. Catalyst aims to address unmet medical needs and provide hope to patients and their families. Through their dedication and commitment, Catalyst Pharmaceuticals Inc strives to make a positive impact in the field of rare disease therapeutics.

Коефициентът на цена спрямо печалбата (КЦП) на Catalyst Pharmaceuticals е 17,11.

Коефициентът на цена към оборот (KUV) на Catalyst Pharmaceuticals е 4,71.

AlleAktien качественият резултат за Catalyst Pharmaceuticals е 6/10.

очаквана Catalyst Pharmaceuticals оборотът е 483,15 млн. USD.

очаквана Catalyst Pharmaceuticals печалба е 132,93 млн. USD.

Catalyst Pharmaceuticals Inc is a US biopharmaceutical company that focuses on the development and marketing of drugs for rare diseases. The company was founded in 2002 and is headquartered in Coral Gables, Florida.

Catalyst Pharmaceuticals разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Catalyst Pharmaceuticals в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Catalyst Pharmaceuticals е US14888U1016.

WKN на Catalyst Pharmaceuticals е A0LCUL.

Тикерът на Catalyst Pharmaceuticals е CPRX.

През последните 12 месеца Catalyst Pharmaceuticals изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Catalyst Pharmaceuticals да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Catalyst Pharmaceuticals в момента е .

Catalyst Pharmaceuticals изплаща дивидент на тримесечие. Той се разпределя в месеците .

Catalyst Pharmaceuticals платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Catalyst Pharmaceuticals се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Catalyst Pharmaceuticals на 6.10.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 6.10.2024 г..

Последното дивидентно плащане беше извършено на 6.10.2024 г..

През година 2023 Catalyst Pharmaceuticals изплати 0 USD под формата на дивиденти.

Дивидентите от Catalyst Pharmaceuticals се изплащат в USD.